Sofinnova Investments Inc. lessened its holdings in Savara Inc. (NASDAQ:SVRA – Free Report) by 87.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 304,770 shares of the company’s stock after selling 2,122,954 shares during the quarter. Sofinnova Investments Inc.’s holdings in Savara were worth $1,838,000 at the end of the most recent quarter.
Several other large investors also recently bought and sold shares of SVRA. Rhumbline Advisers boosted its stake in Savara by 10.8% in the second quarter. Rhumbline Advisers now owns 170,176 shares of the company’s stock valued at $388,000 after acquiring an additional 16,634 shares in the last quarter. Prudential Financial Inc. acquired a new stake in Savara in the second quarter valued at about $30,000. XTX Topco Ltd purchased a new position in Savara in the second quarter valued at about $201,000. Invesco Ltd. lifted its position in shares of Savara by 35.4% during the 2nd quarter. Invesco Ltd. now owns 120,891 shares of the company’s stock valued at $276,000 after acquiring an additional 31,633 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Savara by 14.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 51,930 shares of the company’s stock valued at $118,000 after acquiring an additional 6,449 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.
Savara Stock Performance
Shares of Savara stock opened at $5.33 on Tuesday. The firm has a market cap of $1.09 billion, a PE ratio of -9.52 and a beta of 0.26. Savara Inc. has a 1 year low of $1.98 and a 1 year high of $7.01. The firm’s 50-day simple moving average is $5.28 and its 200-day simple moving average is $5.60. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.47 and a current ratio of 13.47.
Analyst Upgrades and Downgrades
A number of research analysts have recently weighed in on SVRA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research note on Tuesday, April 21st. Oppenheimer began coverage on shares of Savara in a report on Friday, April 24th. They issued an “outperform” rating and a $11.00 price target on the stock. Wall Street Zen upgraded shares of Savara from a “sell” rating to a “hold” rating in a report on Saturday. William Blair set a $10.00 target price on shares of Savara in a report on Monday, March 16th. Finally, HC Wainwright reissued a “buy” rating on shares of Savara in a research report on Monday, March 16th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Savara currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.14.
View Our Latest Stock Report on SVRA
Savara Profile
Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.
The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.
Featured Articles
- Five stocks we like better than Savara
- These 5 Companies Just Made a Massive Bet on Themselves
- 5 Stocks Built to Thrive in a Higher-for-Longer Economy
- RH’s Strong Q1 Still Leaves Investors With One Big Question
- Iran Ceasefire or Not, These 3 Companies Could Win
Want to see what other hedge funds are holding SVRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Savara Inc. (NASDAQ:SVRA – Free Report).
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.
-etf-logo-1200x675.png){kind=logo}
